Determination of cisplatin in blood plasma by liquid chromatography with mass spectrometry detection

Yaroshenko, D. V.; Grigoriev, A. V.; Sidorova, A. A.; Карцова, Л. А.

doi:10.1134/s1061934813020160

Cited by 16 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma Cisplatin in Nonhuman Primates Blood was collected for plasma cisplatin levels prior to dosing and at 0.5, 1, 2, 4, 8 and 24 h after the start of cisplatin infusion on the first and last day of cisplatin treatment. Plasma samples were analyzed for cisplatin by liquid chromatography-tandem mass spectrometry (LC-MS/MS) using a derivatization method based on previously published methods (Tang et al, 2013;Yaroshenko et al, 2013). Post-derivatization, samples were extracted using protein precipitation with acetonitrile and diluted into water containing 0.1% FA (formic acid).…”

Section: Nonhuman Primate Studymentioning

confidence: 99%

GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates

et al. 2020

View full text Add to dashboard Cite

Section: Nonhuman Primate Studymentioning

confidence: 99%

GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates

et al. 2020

View full text Add to dashboard Cite

“…The recovery of IS was more than 87.0%. It was reported earlier that the CP was detected in plasma by using LC‐MS method after the derivatization of drug with diethyldithiocarbamate . On the contrary, we have not derivatized the CP in this study to avoid the complexity of the method.…”

Section: Resultsmentioning

confidence: 98%

“…It was reported earlier that the CP was detected in plasma by using LC-MS method after the derivatization of drug with diethyldithiocarbamate. [33] On the contrary, we have not derivatized the CP in this study to avoid the complexity of the method. Even though the drug was not derivatized with the derivatization reagents, good recovery was achieved in target tissues (>81%).…”

Section: Extraction Recovery and Matrix Effectmentioning

confidence: 99%

Distribution study of cisplatin in rat kidney and liver cancer tissues by using liquid chromatography electrospray ionization tandem mass spectrometry

et al. 2015

View full text Add to dashboard Cite

A sensitive and rapid liquid chromatography positive ion electrospray ionization tandem mass spectrometric (LC/ESI-MS/MS) method has been developed and validated for the quantitative determination and distribution of cisplatin (CP) in kidney and liver tissues after intravenous administration of drug to adult male Sprague Dawley rats. Oxaliplatin (OXP) was used as an internal standard. The tissue samples were homogenized and extracted using conventional liquid-liquid extraction method with phosphate buffer containing ethyl acetate and then subjected to LC-MS analysis. The chromatographic separation was achieved on an Agilent ZORBAX SB C-18 column (50 × 2.1 mm, 1.8 µm) using the mobile phase consisting of 0.1% formic acid in water (Solvent A) : methanol (Solvent B) (40 : 60; v/v) in an isocratic elution followed by detection with positive ion electrospray ionization tandem mass spectrometry using the transitions of m/z 301 > 265 for CP and m/z 398 > 310 for OXP in multiple reaction monitoring mode. The calibration curve was linear in the range of 5.0-7000 and 10.0-6000 ng/ml for kidney and liver tissue homogenates, respectively. The method revealed good performances in terms of within-batch, between-batch precision (1.31-5.70%) and accuracy (97.0-102.24%) for CP in both kidney and liver tissue homogenates including lower and upper limits of quantification. The recoveries from spiked control samples were >81.0% and >87.0 % for CP and OXP, respectively. Matrix effect was found to be negligible, and the stability data were within the acceptable limits. Further, the validated LC/ES-MS/MS method was successfully applied to investigate the distribution of CP in kidney and liver tissues after intravenous administration of CP to male Sprague Dawley rats. The results showed that the higher amount of CP was distributed in kidney followed by liver, which indicated that CP mainly accumulated in kidney tissues and renal excretion might be a primary and main elimination route. This is the first research approach focused on the quantitative determination and distribution of CP in rat kidney and liver tissue homogenates by using LC/ESI-MS/MS, which could provide essential information for further pharmacological and clinical studies of CP.

show abstract

“…However, only poorly detectable ions were found for cisplatin regardless of the types of acid modifiers and solvents employed [1,2,8,40], reflecting the analytical challenges for direct quantitation of cisplatin using LC-MS/MS. Several studies have reported the use of pre-column derivatization of cisplatin for LC-MS/MS quantitation [41][42][43]. Although this approach can promote the ionization of cisplatin, it results in a measurement of cisplatin together with other Pt-based complexes aforementioned.…”

Section: Introductionmentioning

confidence: 99%

Zwitterionic hydrophilic interaction liquid chromatography-tandem mass spectrometry with HybridSPE-precipitation for the determination of intact cisplatin in human plasma

Xie

Colin

Bocxlaer

2017

Talanta

View full text Add to dashboard Cite

Cisplatin is a first-line chemotherapeutic for the treatment of a wide variety of cancers since its discovery in the 1960s. Although various techniques have been reported for the measurement of total platinum in biological matrices, such as inductively coupled plasma-mass spectrometry and derivatization procedures, a specific, sensitive and robust assay for the quantification of intact cisplatin is still lacking. Therefore, we present a rapid, selective, sensitive, and reliable UHPLC-MS/MS based method for the determination of intact cisplatin in human plasma in support of a Phase II clinical trial. The optimal chromatographic behavior of cisplatin was achieved on a Syncronis HILIC column (50 × 2.1mm, 1.7µm, zwitterionic stationary phase). The retention behavior of cisplatin on this zwitterion-based stationary phase was well described by an adsorptive interaction model. A simple sample preparation based on protein precipitation combined with the removal of phospholipids by HybridSPE-precipitation was developed. The method was proven to be free of a relative matrix effect. The assay was validated within a range of 20 - 10,000ng/mL using 100μL of plasma sample. The intra and inter-day precisions were all less than 7.6%, and none of the bias was greater than 13.1%, thus corroborating that the developed method is precise and accurate. As a proof of concept, the assay has been successfully applied to plasma samples obtained from different patients who were enrolled in the Phase II trial and were treated with cisplatin.

show abstract

Determination of cisplatin in blood plasma by liquid chromatography with mass spectrometry detection

Cited by 16 publications

References 15 publications

GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates

GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates

Distribution study of cisplatin in rat kidney and liver cancer tissues by using liquid chromatography electrospray ionization tandem mass spectrometry

Zwitterionic hydrophilic interaction liquid chromatography-tandem mass spectrometry with HybridSPE-precipitation for the determination of intact cisplatin in human plasma

Contact Info

Product

Resources

About